, joins Pieris as Chief Medical Officer * Shane Olwill, Ph., promoted to Chief Development OfficerBOSTON,MA / ACCESSWIRE / August 3,2021 /Pieris Pharmaceuticals, Inc.
|
Zahlen für Q2/21
www.pieris.com/news-media/press-releases/...cond-quarter-2021
es gab Mäuse-News in Covid Zeiten
Meine Meinung - KEINE Handelsempfehlung.
- PRS-060: Dosing completed in part 1a of phase 2a study of AZD1402
- PRS-343: Dosing to begin this quarter in phase 2 study of cinrebafusp alfa
- PRS-344: Received regulatory approval from multiple countries for phase 1/2 study of S095012
- Presented preclinical data for PRS-220 at ERS; on track for 2022 clinical initiation
- Initiated second costim bispecific program in Seagen collaboration
- Initiated respiratory and ophthalmology programs with Genentech
- Promoted Thomas Bures to CFO and Ahmed Mousa to CBO
Webcast heute 13:00 Uhr
Zahlen für Q3/21
www.pieris.com/investors/news-events/...uarter-2021-financial
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 444 | Pieris Pharmaceuticals ...7 - 8 USD sind drin?! | Balu4u | iTechDachs | 27.03.24 21:24 | |
8 | Pieris | BICYPAPA | iTechDachs | 17.05.19 12:03 |